Concordia Healthcare Corp. (NASDAQ:CXRX) shares hit a new 52-week low on Thursday . The company traded as low as $8.41 and last traded at $8.48, with a volume of 355,381 shares changing hands. The stock had previously closed at $8.71.

A number of brokerages have recently weighed in on CXRX. Canaccord Genuity restated a “buy” rating on shares of Concordia Healthcare Corp. in a research report on Sunday, June 26th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $73.00 price target on shares of Concordia Healthcare Corp. in a research report on Thursday, May 26th. Zacks Investment Research upgraded Concordia Healthcare Corp. from a “sell” rating to a “hold” rating in a research report on Monday, May 30th. Goldman Sachs Group Inc. dropped their price target on Concordia Healthcare Corp. from $26.00 to $13.00 and set a “neutral” rating for the company in a research report on Monday, August 15th. Finally, GMP Securities lowered Concordia Healthcare Corp. from a “buy” rating to a “hold” rating in a research report on Monday, August 15th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $39.87.

The stock’s market capitalization is $431.09 million. The stock has a 50 day moving average of $14.65 and a 200 day moving average of $23.75.

Concordia Healthcare Corp. (NASDAQ:CXRX) last released its quarterly earnings results on Friday, August 12th. The company reported $1.38 earnings per share for the quarter, hitting the consensus estimate of $1.38. The company had revenue of $231.70 million for the quarter, compared to analyst estimates of $229.76 million. The business’s revenue was up 208.1% on a year-over-year basis. On average, analysts forecast that Concordia Healthcare Corp. will post $5.35 EPS for the current year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.